Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 2:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Lundbeck LLC Clear all
Completed Phase 4 Interventional Results available

A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)

NCT01278173
View directory record Official record
Conditions
Adult Refractory Complex Partial Seizures
Interventions
Sabril
Drug
Lead sponsor
Lundbeck LLC
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
22
States / cities
San Francisco, California • New Haven, Connecticut • Dover, Delaware + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Sep 28, 2026, 2:12 AM EDT
Terminated Phase 3 Interventional

Clobazam Use in Epilepsia Partialis Continua - Pilot Study

NCT02134366
View directory record Official record
Conditions
Epilepsia Partialis Continua, Kojewnikov's Epilepsy, Epilepsy
Interventions
Clobazam, Clonazepam, Lorazepam
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Sep 28, 2026, 2:12 AM EDT
Completed No phase listed Observational

Electrical Status Epilepticus in Sleep: Response of Neuropsychological Deficits and Epileptiform Activity to Clobazam Treatment

NCT02127918
View directory record Official record
Conditions
Electrical Status Epilepticus in Sleep
Interventions
ESES treated with clobazam
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 4 Interventional Results available

Lundbeck TOMs Orthostatic Hypotension

NCT04510922
View directory record Official record
Conditions
Orthostatic Hypotension, Idiopathic Parkinson Disease
Interventions
Droxidopa 100 MG [Northera]
Drug
Lead sponsor
Alberto Espay, MD, MSc
Other
Eligibility
30 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers

NCT04928703
View directory record Official record
Conditions
Healthy
Interventions
Ketamine
Drug
Lead sponsor
ERP Biomarker Qualification Consortium
Industry
Eligibility
21 Years to 40 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 28, 2026, 2:12 AM EDT
Completed No phase listed Observational Results available

Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease

NCT01451463
View directory record Official record
Conditions
Huntington's Disease
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 4 Interventional

Brain Perfusion & Oxygenation in Parkinson's Disease With NOH

NCT03229174
View directory record Official record
Conditions
Parkinson Disease, Neurogenic Orthostatic Hypotension
Interventions
Droxidopa, Placebo
Drug
Lead sponsor
William Ondo, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2022 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Results available

Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease

NCT00125138
View directory record Official record
Conditions
Parkinson's Disease, Psychotic Disorders
Interventions
Melperone HCl, Placebo
Drug
Lead sponsor
Lundbeck LLC
Industry
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
10
States / cities
Tucson, Arizona • Bradenton, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Sep 28, 2026, 2:12 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia

NCT06604520
View directory record Official record
Conditions
Fronto-temporal Dementia, Fronto-temporal Lobar Dementia, Frontotemporal Degeneration, Frontotemporal Dementia (FTD), Frontotemporal Dementia, Behavioral Variant, Frontotemporal Dementia
Interventions
Vortioxetine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

Clobazam in Patients With Lennox-Gastaut Syndrome

NCT00518713
View directory record Official record
Conditions
Epilepsy, Epilepsy, Generalized, Seizures
Interventions
Clobazam Low Dose, Clobazam Medium Dose, Clobazam High Dose, Placebo
Drug
Lead sponsor
Lundbeck LLC
Industry
Eligibility
2 Years to 60 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
34
States / cities
Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Sep 28, 2026, 2:12 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS)

NCT02558972
View directory record Official record
Conditions
Postural Tachycardia Syndrome (POTS), Vasovagal Syncope (VVS), Fainting
Interventions
Northera (Droxidopa), Placebo
Drug
Lead sponsor
New York Medical College
Other
Eligibility
18 Years to 35 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 28, 2026, 2:12 AM EDT
Not listed Phase 4 Interventional

Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy

NCT02726919
View directory record Official record
Conditions
Epilepsy
Interventions
Clobazam
Drug
Lead sponsor
Pavel Klein
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 28, 2026, 2:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Healthy Volunteer Subjects

NCT04025502
View directory record Official record
Conditions
Schizophrenia
Interventions
Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System
Device
Lead sponsor
ERP Biomarker Qualification Consortium
Industry
Eligibility
21 Years to 50 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Garden Grove, California • Torrance, California • Marlton, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Results available

Clobazam in Subjects With Lennox-Gastaut Syndrome

NCT00162981
View directory record Official record
Conditions
Epilepsy, Epilepsy, Generalized, Seizures
Interventions
Clobazam Low Dose, Clobazam High Dose
Drug
Lead sponsor
Lundbeck LLC
Industry
Eligibility
2 Years to 30 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Not applicable Interventional Results available

Use of a Digitally Enabled App With Clinical Team Interface in the Management of Depression

NCT04891224
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Pathway Platform mobile app
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy

NCT01128959
View directory record Official record
Conditions
Epilepsy
Interventions
Intravenous Carbamazepine (IV CBZ)
Drug
Lead sponsor
Lundbeck LLC
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
29
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Torrance, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced Sep 28, 2026, 2:12 AM EDT